OD-003 / Odyssey Therap - LARVOL DELTA

TNFR2 Agonist OD-003 Expands Immunosuppressive Tissue Treg and Has the Potential to Treat Autoimmune and Inflammatory Disease (ACR Convergence 2026) - "OD-003 selectively expands stable Treg that are able to migrate into disease tissue and could result in improved efficacy for autoimmune disease treatment vs IL-2-based therapeutic approaches."

Alopecia • Atopic Dermatitis • CNS Disorders • Dermatitis • Immunology • Inflammation • Inflammatory Arthritis • Multiple Sclerosis • BATF • FOXP3

Odyssey Therapeutics Discloses…Details Pipeline Timelines and Cash Runway in New SEC Filing (Minichart) - "For OD-002, an oral SLC15A4 inhibitor targeting B cell-mediated diseases, the company announced it is on track to file a Clinical Trial Application (CTA) in H2 2026 and initiate a Phase 1/2 trial in H1 2027. The trial will initially evaluate the drug in cutaneous lupus erythematosus (CLE). Efficacy readouts from the Phase 2a portion are expected in H2 2028....The company’s preclinical TNFR2 agonist program, OD-003, is currently in IND-enabling studies, targeting indications like atopic dermatitis and alopecia areata."

New P1/2 trial • P2a data • Preclinical • Alopecia • Atopic Dermatitis • Cutaneous Lupus Erythematosus • Immunology